Journal of Antivirals & Antiretrovirals
Open Access
ISSN: 1948-5964
+44 1300 500008
ISSN: 1948-5964
+44 1300 500008
Department of Infectious Disease and Clinical Microbiology, Erzincan Binali Yildirim University, Erzincan, Turkey
Research Article
Level of SARS-CoV-2 IgG Antibodies after a Single Dose CoronaVac Vaccine: Primarily Report
Author(s): Umut Devrim Binay*, Faruk Karakecili, Orcun Barkay, Ozlem Gul and Cuma Mertoglu
Background: It is necessary to use an effective vaccine to end the COVID-19 pandemic. CoronaVac vaccine is used
in our country and we aimed to examine the level of antibody development after the first dose.
Methods: This is a retrospective, cross-sectional research. The data of the people, who applied to a university hospital
between January and February 2021,were analyzed. Those who had SARS-CoV-2 IgG and IgM measurement in
the previous two weeks before the CoronoVac vaccine, and those who were both found negative and who had
SARS-CoV-2 IgG and IgM measurement after the first dose of CoronaVac vaccine were included in the research.
SARS-CoV-2 IgG/IgM were measured by VIDAS® (BioMérieux, Marcy-l'Etoile, France) device for the detection of
spike protein specific IgG/IgM of SARS-CoV-2 in human serum with E.. View More»
DOI:
10.35248/1948-5964.21.s18.004